An Innovative Systematic Approach Introduced the Involved Lncrna-Mir-Mrna Network in Cell Cycle and Proliferation After Conventional Treatments in Breast Cancer Patients Publisher Pubmed



Mohsenikia M¹ ; Khalighfard S² ; Alizadeh AM^{3, 4} ; Khori V⁵ ; Ghandian Zanjan M⁵ ; Zare M⁵ ; Omranipour R³ ; Patrad E⁴ ; Razavi H⁴ ; Malekshahi ZV⁶ ; Bagherihosseinabadi Z⁷ Show Affiliations
Source: Cell Cycle Published:2022

Abstract

The present study aimed to explore the involved lncRNA-miRNA-mRNA network in the cell cycle and proliferation after conventional treatments in Luminal A breast cancer patients.The candidate miRNAs (miRs), lncRNAs, and mRNAs were first taken from the Gene Expression Omnibus and TCGA databases. The lncRNA–miR–mRNA network was then constructed using the high-throughput sequencing data. The expression levels of selected targets were measured in the breast cancer and healthy samples by the Real-Time PCR technique and compared with the clinical outcomes by the Kaplan-Meier method.Our analysis revealed a group of differentially expressed 3 lncRNAs, 9 miRs, and 14 mRNAs in breast cancer patients. A significant expression decrease of the selected tumor suppressor lncRNAs, miRs, and genes and a substantial expression increase of the selected onco-lncRNAs, oncomiRs, and oncogenes were obtained in the patients compared to the healthy group. The plasma levels of the lncRNAs, miRs, and mRNAs were more significant after the operation, chemotherapy, and radiotherapy than the pre-treatment. The Kaplan-Meier analysis indicated that the patients with a high expression of miR-21, miR-20b, IGF1R, and E2F2 and a low expression of miR-125a, PDCD4, and PTEN had exhibited a shorter overall survival rate.Our results suggested that the underlying mechanisms of the lncRNA, miRs, and mRNAs and relevant signaling pathways may be considered predictive and therapeutic targets for breast cancer. © 2022 Informa UK Limited, trading as Taylor & Francis Group.